CSL BEHRING LLC for CSL BEHRING LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA for licensure HR 5376--Inflation Reduction Act--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of Build Back Better Act. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of Prescription Drug User Fee Act VII specific to FDA user fees.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Immigration IMM
Customs and Border Protection policy change on allowing B1/B2 visa holders to cross the US border to donate plasma.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Taxation/Internal Revenue Code TAX
HR 5376--Inflation Reduction Act--Sought to have language stricken that would limit the Orphan Drug Tax Credit to solely the first product indication for a therapy. Also sought to include language that would delay the requirement to amortize Research & Development expenses over 5 years instead of obtaining an immediate deduction from taxable income.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.